Persons manufacturing or marketing the substances, plants, medicinal products and other products mentioned in article R. 5132-98 shall, at their request, provide the Director General of the Agence nationale de sécurité du médicament et des produits de santé with all information relating to drug dependence and abuse concerning their products, as well as information concerning their sale.